Ocugen Announces Preliminary 12-Month Data From Phase 2 ArMaDa Clinical Trial Evaluating OCU410 For GA Secondary To Dry Age-Related Macular Degeneration
Benzinga Newsdesk 9 months ago
News
Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious adverse events reported across the Phase 1 and Phase 2 clinical trials to
- Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. control
- There are no OCU410-related serious adverse events reported across the Phase 1 and Phase 2 clinical trials to date
MALVERN, Pa., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced positive preliminary 12-month data (~50% of patients evaluated to date) from the Phase 2 ArMaDa clinical trial evaluating OCU410 (AAV5-RORA), its novel modifier gene therapy for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD). The global prevalence of dAMD is 266 million worldwide, and GA – the late stage of dAMD – affects approximately 2-3 million people in the United States (U.S.) and Europe.
There are limited options for patients with dAMD in the U.S. and current therapies involve frequent (monthly or every other month) injections and have unwanted side effects that can affect vision. Outside of the U.S., there are no approved products available, leaving approximately 2 million patients in Europe without a treatment option.